HDAC inhibitors (HDACi) are candidate drugs to treat DLBCL patients with elevated MYC in combination with enhanced BCL2 levels, thereby deregulating MYC expression and activity [181,182,183]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.